

# Debby Van Dam

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9450376/debby-van-dam-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

123  
papers

4,805  
citations

35  
h-index

67  
g-index

127  
ext. papers

5,443  
ext. citations

4.8  
avg, IF

5.74  
L-index

#	Paper	IF	Citations
123	Age-related cognitive decline in spatial learning and memory of C57BL/6J mice. <i>Behavioural Brain Research</i> , <b>2022</b> , 418, 113649	3.4	1
122	Animal Models for Brain Research <b>2021</b> , 3-55		
121	Inflammation, Nitro-Oxidative Stress, Impaired Autophagy, and Insulin Resistance as a Mechanistic Convergence Between Arterial Stiffness and Alzheimer's Disease. <i>Frontiers in Molecular Biosciences</i> , <b>2021</b> , 8, 651215	5.6	6
120	Serum Corticosterone and Insulin Resistance as Early Biomarkers in the hAPP23 Overexpressing Mouse Model of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	5
119	The Behavioral and Psychological Symptoms of Dementia in Down Syndrome Scale (BPSD-DS II): Optimization and Further Validation. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 81, 1505-1527	4.3	5
118	Altered stress hormone levels affect in vivo vascular function in the hAPP23 overexpressing mouse model of Alzheimer's disease. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2021</b> , 321, H905-H919	5.2	0
117	5-HT receptors in Alzheimer's disease. <i>Neurochemistry International</i> , <b>2021</b> , 150, 105185	4.4	3
116	Pentylentetrazole-induced Seizure Susceptibility in the Tau58/4 Transgenic Mouse Model of Tauopathy. <i>Neuroscience</i> , <b>2020</b> , 425, 112-122	3.9	7
115	Progressive tau aggregation does not alter functional brain network connectivity in seeded hTau.P301L mice. <i>Neurobiology of Disease</i> , <b>2020</b> , 143, 105011	7.5	4
114	Comparison of size distribution and (Pro249-Ser258) epitope exposure in in vitro and in vivo derived Tau fibrils. <i>BMC Molecular and Cell Biology</i> , <b>2020</b> , 21, 81	2.7	2
113	Intrathecal cerebrospinal fluid infusion as a potential therapeutic strategy for Alzheimer's disease. <i>Medical Hypotheses</i> , <b>2019</b> , 122, 57	3.8	
112	Alzheimer's disease and glaucoma: Look-alike neurodegenerative diseases. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 600-601	1.2	5
111	Nitric oxide donor molsidomine favors features of atherosclerotic plaque stability and reduces myocardial infarction in mice. <i>Vascular Pharmacology</i> , <b>2019</b> , 118-119, 106561	5.9	9
110	PTZ-induced seizures in mice require a revised Racine scale. <i>Epilepsy and Behavior</i> , <b>2019</b> , 95, 51-55	3.2	54
109	Evaluating the applicability of mouse SINEs as an alternative normalization approach for RT-qPCR in brain tissue of the APP23 model for Alzheimer's disease. <i>Journal of Neuroscience Methods</i> , <b>2019</b> , 320, 128-137	3	5
108	The validation of Short Interspersed Nuclear Elements (SINEs) as a RT-qPCR normalization strategy in a rodent model for temporal lobe epilepsy. <i>PLoS ONE</i> , <b>2019</b> , 14, e0210567	3.7	5
107	Neuroimaging of Subacute Brain Inflammation and Microstructural Changes Predicts Long-Term Functional Outcome after Experimental Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , <b>2019</b> , 36, 768-788	5.4	18

106	Alzheimer's disease: Neurotransmitters of the sleep-wake cycle. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2019</b> , 105, 72-80	9	16
105	Sleep architecture changes in the APP23 mouse model manifest at onset of cognitive deficits. <i>Behavioural Brain Research</i> , <b>2019</b> , 373, 112089	3.4	8
104	Everolimus depletes plaque macrophages, abolishes intraplaque neovascularization and improves survival in mice with advanced atherosclerosis. <i>Vascular Pharmacology</i> , <b>2019</b> , 113, 70-76	5.9	10
103	Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease. <i>Journal of Parkinsons Disease</i> , <b>2018</b> , 8, 71-84	5.3	10
102	Fibromyalgia as a glymphatic overload syndrome. <i>Medical Hypotheses</i> , <b>2018</b> , 115, 17-18	3.8	1
101	Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2018</b> , 10, 172-181	5.2	13
100	Serotonergic Dysfunction in Amyotrophic Lateral Sclerosis and Parkinson's Disease: Similar Mechanisms, Dissimilar Outcomes. <i>Frontiers in Neuroscience</i> , <b>2018</b> , 12, 185	5.1	19
99	Anti-Tau Monoclonal Antibodies Derived from Soluble and Filamentous Tau Show Diverse Functional Properties in vitro and in vivo. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 65, 265-281	4.3	22
98	Letter to the Editor. Low ICP and normal tension glaucoma: optic nerve damage due to barotraumatic factors, failure of CSF dynamics, or both?. <i>Journal of Neurosurgery</i> , <b>2018</b> , 129, 1100-1103	3.2	
97	Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2018</b> , 10, 99-111	5.2	4
96	Sleep and Alzheimer's disease: A pivotal role for the suprachiasmatic nucleus. <i>Sleep Medicine Reviews</i> , <b>2018</b> , 40, 17-27	10.2	45
95	The First Histologic Evidence of a Paravascular Pathway Within the Optic Nerve <b>2018</b> , 59, 1717		8
94	Intracranial pressure and glaucoma: Is there a new therapeutic perspective on the horizon?. <i>Medical Hypotheses</i> , <b>2018</b> , 118, 98-102	3.8	7
93	Alzheimer's disease and glaucoma: can glymphatic system dysfunction underlie their comorbidity?. <i>Acta Ophthalmologica</i> , <b>2017</b> , 95, e244-e245	3.7	6
92	Progressive Motor Deficit is Mediated by the Denervation of Neuromuscular Junctions and Axonal Degeneration in Transgenic Mice Expressing Mutant (P301S) Tau Protein. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 60, S41-S57	4.3	17
91	Accelerated high-frequency repetitive transcranial magnetic stimulation enhances motor activity in rats. <i>Neuroscience</i> , <b>2017</b> , 347, 103-110	3.9	13
90	Impaired hypoxic tolerance in APP23 mice: a dysregulation of neuroprotective globin levels. <i>FEBS Letters</i> , <b>2017</b> , 591, 1321-1332	3.8	5
89	Immune hyperreactivity of A $\beta$ plaque-associated microglia in Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2017</b> , 55, 115-122	5.6	132

88	Behavioural characterization of AnkyrinG deficient mice, a model for ANK3 related disorders. <i>Behavioural Brain Research</i> , <b>2017</b> , 328, 218-226	3.4	14
87	Do repetitive Valsalva maneuvers reduce glymphatic clearance?. <i>Annals of Neurology</i> , <b>2017</b> , 81, 322	9.4	2
86	Non human primate models for Alzheimer's disease-related research and drug discovery. <i>Expert Opinion on Drug Discovery</i> , <b>2017</b> , 12, 187-200	6.2	34
85	"Hypodense Holes" and the Ocular Glymphatic System: Author Response: "Black Holes" and the Ocular Glymphatic System <b>2017</b> , 58, 1132-1133		
84	The Glymphatic Hypothesis of Glaucoma: A Unifying Concept Incorporating Vascular, Biomechanical, and Biochemical Aspects of the Disease. <i>BioMed Research International</i> , <b>2017</b> , 2017, 5123-5148	3.148	1029
83	Adapted Morris Water Maze protocol to prevent interference from confounding motor deficits on cognitive functioning. <i>Somatosensory &amp; Motor Research</i> , <b>2017</b> , 34, 172-178	1.2	6
82	Evidence for the existence of a communication between the eye and the brain?. <i>Acta Neurochirurgica</i> , <b>2017</b> , 159, 1413-1414	3	2
81	Aging rather than aneuploidy affects monoamine neurotransmitters in brain regions of Down syndrome mouse models. <i>Neurobiology of Disease</i> , <b>2017</b> , 105, 235-244	7.5	10
80	The two faces of the translaminal pressure difference: the biomechanical one and the biochemical one. <i>Australasian journal of optometry, The</i> , <b>2017</b> , 100, 102-103	2.7	2
79	Aging, microglia and cytoskeletal regulation are key factors in the pathological evolution of the APP23 mouse model for Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2017</b> , 1863, 395-405	6.9	9
78	Increased White Matter Inflammation in Aging- and Alzheimer's Disease Brain. <i>Frontiers in Molecular Neuroscience</i> , <b>2017</b> , 10, 206	6.1	101
77	Neutrophil Gelatinase-Associated Lipocalin and its Receptors in Alzheimer's Disease (AD) Brain Regions: Differential Findings in AD with and without Depression. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 55, 763-776	4.3	22
76	Cerebral and cerebellar language organization in a right-handed subject with a left temporal porencephalic cyst: An fMRI study. <i>Journal of Neurolinguistics</i> , <b>2016</b> , 37, 41-46	1.9	
75	Age-related macular degeneration, glaucoma and Alzheimer's disease: amyloidogenic diseases with the same glymphatic background?. <i>Cellular and Molecular Life Sciences</i> , <b>2016</b> , 73, 4299-4301	10.3	16
74	Dilated Virchow-Robin spaces in primary open-angle glaucoma: a biomarker of glymphatic waste clearance dysfunction?. <i>Acta Radiologica Open</i> , <b>2016</b> , 5, 2058460116653630	1.2	2
73	Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?. <i>Current Alzheimer Research</i> , <b>2016</b> , 13, 1145-64	3	36
72	The Glymphatic System: A New Player in Ocular Diseases? <b>2016</b> , 57, 5426-5427		33
71	A General Decline in Cerebrospinal Fluid Flow: An Overlooked Risk Factor for Glaucoma?. <i>Journal of Neuro-Ophthalmology</i> , <b>2016</b> , 36, 227-8	2.6	

70	A general decline in cerebrospinal fluid flow and optic nerve compartmentation: are these sequential steps leading to toxicity in normal-tension glaucoma?. <i>Acta Ophthalmologica</i> , <b>2016</b> , 94, e242-3	3.7	2
69	Fast circulation of cerebrospinal fluid: an alternative perspective on the protective role of high intracranial pressure in ocular hypertension. <i>Australasian journal of optometry, The</i> , <b>2016</b> , 99, 213-8	2.7	9
68	Specific Triazine Herbicides Induce Amyloid- $\beta$ Production. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 54, 1593-1605	4.3	11
67	Brain Serotonergic and Noradrenergic Deficiencies in Behavioral Variant Frontotemporal Dementia Compared to Early-Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 53, 1079-96	4.3	25
66	Late age increase in soluble amyloid-beta levels in the APP23 mouse model despite steady-state levels of amyloid-beta-producing proteins. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2016</b> , 1862, 105-12	6.9	8
65	The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2015</b> , 7, 7	9	30
64	Impaired gait pattern as a sensitive tool to assess hypoxic brain damage in a novel mouse model of atherosclerotic plaque rupture. <i>Physiology and Behavior</i> , <b>2015</b> , 139, 397-402	3.5	13
63	Signal loss due to oligomerization in ELISA analysis of amyloid-beta can be recovered by a novel sample pre-treatment method. <i>MethodsX</i> , <b>2015</b> , 2, 112-23	1.9	14
62	The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome. <i>Cell Cycle</i> , <b>2015</b> , 14, 2985-95	4.7	68
61	Brain inflammation in a chronic epilepsy model: Evolving pattern of the translocator protein during epileptogenesis. <i>Neurobiology of Disease</i> , <b>2015</b> , 82, 526-539	7.5	57
60	Behavioural and psychological symptoms of dementia in Down syndrome: Early indicators of clinical Alzheimer's disease?. <i>Cortex</i> , <b>2015</b> , 73, 36-61	3.8	62
59	Serum MHPG strongly predicts conversion to Alzheimer's disease in behaviorally characterized subjects with Down syndrome. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 43, 871-91	4.3	25
58	Serum NGAL is Associated with Distinct Plasma Amyloid- $\beta$ Peptides According to the Clinical Diagnosis of Dementia in Down Syndrome. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 45, 733-43	4.3	17
57	A multidisciplinary approach unravels early and persistent effects of X-ray exposure at the onset of prenatal neurogenesis. <i>Journal of Neurodevelopmental Disorders</i> , <b>2015</b> , 7, 3	4.6	26
56	A new glaucoma hypothesis: a role of glymphatic system dysfunction. <i>Fluids and Barriers of the CNS</i> , <b>2015</b> , 12, 16	7	66
55	Glaucoma and the Role of Cerebrospinal Fluid Dynamics <b>2015</b> , 56, 6630-1		8
54	Acute modulation of the cholinergic system in the mouse brain detected by pharmacological resting-state functional MRI. <i>NeuroImage</i> , <b>2015</b> , 109, 151-9	7.9	26
53	Intracranial pressure fluctuations: a potential risk factor for glaucoma?. <i>Acta Ophthalmologica</i> , <b>2015</b> , 93, e83-4	3.7	7

52	The role of low intracranial pressure in the development of glaucoma in patients with Alzheimer's disease. <i>Progress in Retinal and Eye Research</i> , <b>2014</b> , 39, 107-8	20.5	7
51	Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 2691-2700	5.6	52
50	Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 41, 819-33	4.3	43
49	Glaucoma considered as an imbalance between production and clearance of neurotoxins <b>2014</b> , 55, 5351-2		19
48	Psychiatric Disorders in Dementia <b>2014</b> , 271-324		1
47	Animal Models for Brain Research <b>2014</b> , 3-46		
46	Novel and sensitive reversed-phase high-pressure liquid chromatography method with electrochemical detection for the simultaneous and fast determination of eight biogenic amines and metabolites in human brain tissue. <i>Journal of Chromatography A</i> , <b>2014</b> , 1353, 28-39	4.5	29
45	Senescent changes in cerebrospinal fluid circulatory physiology and their role in the pathogenesis of normal-tension glaucoma. <i>American Journal of Ophthalmology</i> , <b>2013</b> , 156, 5-14.e2	4.9	45
44	A behavioural study of neuroglobin-overexpressing mice under normoxic and hypoxic conditions. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , <b>2013</b> , 1834, 1764-71	4	11
43	Aripiprazole in the treatment of Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 459-74		39
42	Neuropeptides in Alzheimer's disease: from pathophysiological mechanisms to therapeutic opportunities. <i>Current Alzheimer Research</i> , <b>2013</b> , 10, 449-68	3	13
41	Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. <i>Behavioural Brain Research</i> , <b>2012</b> , 229, 244-9	3.4	89
40	Cellular ageing, increased mortality and FTL-D-TDP-associated neuropathology in progranulin knockout mice. <i>Journal of Pathology</i> , <b>2012</b> , 228, 67-76	9.4	92
39	Behavioral Validation in Animal Models of Dementia. <i>NeuroMethods</i> , <b>2011</b> , 143-154	0.4	
38	Genes involved in cerebrospinal fluid production as candidate genes for late-onset Alzheimer's disease: a hypothesis. <i>Journal of Neurogenetics</i> , <b>2011</b> , 25, 195-200	1.6	10
37	Increased Cerebrospinal Fluid Production as a Possible Mechanism Underlying Caffeine's Protective Effect against Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , <b>2011</b> , 2011, 617420	3.7	22
36	Region- and age-specific changes in glutamate transport in the APP23 mouse model for Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2011</b> , 24, 287-300	4.3	77
35	Animal models in the drug discovery pipeline for Alzheimer's disease. <i>British Journal of Pharmacology</i> , <b>2011</b> , 164, 1285-300	8.6	140

34	Morphological changes in the enteric nervous system of aging and APP23 transgenic mice. <i>Brain Research</i> , <b>2011</b> , 1378, 43-53	3.7	30
33	Comparison of extraction methods for peptidomics analysis of mouse brain tissue. <i>Journal of Neuroscience Methods</i> , <b>2011</b> , 197, 231-7	3	16
32	The Role of Rodent Models in the Drug Discovery Pipeline for Dementia. <i>Neuromethods</i> , <b>2011</b> , 35-49	0.4	1
31	APP-Based Transgenic Models: The APP23 Model. <i>Neuromethods</i> , <b>2011</b> , 399-413	0.4	
30	General Introduction to Animal Models of Human Conditions. <i>Neuromethods</i> , <b>2011</b> , 3-13	0.4	
29	Species, Strain, and Gender Issues in the Development and Validation of Animal Models of Dementia. <i>Neuromethods</i> , <b>2011</b> , 53-75	0.4	
28	Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. <i>Molecular Therapy</i> , <b>2010</b> , 18, 44-53	11.7	128
27	Excitatory amino acids and monoaminergic neurotransmitters in cerebrospinal fluid of acute ischemic stroke patients. <i>Neurochemistry International</i> , <b>2010</b> , 56, 865-70	4.4	15
26	Central administration of obestatin fails to show inhibitory effects on food and water intake in mice. <i>Regulatory Peptides</i> , <b>2009</b> , 156, 77-82		31
25	Age-dependent changes in noradrenergic locus coeruleus system in wild-type and APP23 transgenic mice. <i>Neuroscience Letters</i> , <b>2009</b> , 463, 93-7	3.3	12
24	Intraneuronal amyloid beta and reduced brain volume in a novel APP T714I mouse model for Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2008</b> , 29, 241-52	5.6	48
23	Evaluation of the APP23-model for Alzheimer's disease in the odour paired-associate test for hippocampus-dependent memory. <i>Behavioural Brain Research</i> , <b>2008</b> , 190, 147-51	3.4	14
22	Validation of the APP23 transgenic mouse model of Alzheimer's disease through evaluation of risperidone treatment on aggressive behaviour. <i>Arzneimittelforschung</i> , <b>2008</b> , 58, 265-8		6
21	Altered ingestive behavior, weight changes, and intact olfactory sense in an APP overexpression model. <i>Behavioral Neuroscience</i> , <b>2008</b> , 122, 491-7	2.1	39
20	Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer's disease. <i>Psychopharmacology</i> , <b>2008</b> , 197, 37-43	4.7	31
19	Mood and male sexual behaviour in the APP23 model of Alzheimer's disease. <i>Behavioural Brain Research</i> , <b>2007</b> , 180, 146-51	3.4	31
18	Decreased expression of the GABAA receptor in fragile X syndrome. <i>Brain Research</i> , <b>2006</b> , 1121, 238-45	3.7	250
17	Actigraphic measurement of agitated behaviour in dementia. <i>International Journal of Geriatric Psychiatry</i> , <b>2006</b> , 21, 388-93	3.9	44

16	Intracerebral adeno-associated virus-mediated gene transfer in rapidly progressive forms of metachromatic leukodystrophy. <i>Human Molecular Genetics</i> , <b>2006</b> , 15, 53-64	5.6	71
15	Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model. <i>European Neuropsychopharmacology</i> , <b>2006</b> , 16, 59-69	1.2	63
14	APP23 mice display working memory impairment in the plus-shaped water maze. <i>Neuroscience Letters</i> , <b>2006</b> , 407, 6-10	3.3	19
13	Effect of Morris water maze diameter on visual-spatial learning in different mouse strains. <i>Neurobiology of Learning and Memory</i> , <b>2006</b> , 85, 164-72	3.1	73
12	Aggressive male APP23 mice modeling behavioral alterations in dementia. <i>Behavioral Neuroscience</i> , <b>2006</b> , 120, 1380-3	2.1	29
11	Drug discovery in dementia: the role of rodent models. <i>Nature Reviews Drug Discovery</i> , <b>2006</b> , 5, 956-70	64.1	158
10	Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models. <i>Neurochemistry International</i> , <b>2005</b> , 46, 409-22	4.4	38
9	Cognitive decline, neuromotor and behavioural disturbances in a mouse model for fragile-X-associated tremor/ataxia syndrome (FXTAS). <i>Behavioural Brain Research</i> , <b>2005</b> , 162, 233-9	3.4	99
8	GSA: behavioral, histological, electrophysiological and neurochemical effects. <i>Physiology and Behavior</i> , <b>2005</b> , 84, 251-64	3.5	13
7	Biochemical and behavioural phenotyping of a mouse model for GAMT deficiency. <i>Journal of the Neurological Sciences</i> , <b>2005</b> , 231, 49-55	3.2	29
6	APP23 mice as a model of Alzheimer's disease: an example of a transgenic approach to modeling a CNS disorder. <i>CNS Spectrums</i> , <b>2005</b> , 10, 207-22	1.8	46
5	Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. <i>Psychopharmacology</i> , <b>2005</b> , 180, 177-90	4.7	100
4	Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances. <i>European Journal of Neuroscience</i> , <b>2004</b> , 20, 2757-66	3.5	71
3	Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. <i>European Journal of Neuroscience</i> , <b>2003</b> , 17, 388-96	3.5	197
2	Hyperactivity, neuromotor defects, and impaired learning and memory in a mouse model for metachromatic leukodystrophy. <i>Brain Research</i> , <b>2001</b> , 907, 35-43	3.7	38
1	Spatial learning, contextual fear conditioning and conditioned emotional response in Fmr1 knockout mice. <i>Behavioural Brain Research</i> , <b>2000</b> , 117, 127-36	3.4	116